T he pentraxin (PTX) family includes 2 subgroups of proteins that are structurally divided into short and long forms, are encoded by different genes, and are produced by different cells. 1-3 PTX3 is the prototype of the long PTX group, which differs from short PTXs by the presence of an unrelated long N-terminal domain giving it a different ligand recognition capacity. 4 PTX3 is highly conserved from mouse to humans (82% identical and 92% conserved amino acids) and is induced by primary inflammatory stimuli in a variety of cell types, 5,6 including mononuclear phagocytes, fibroblasts, adipocytes, dendritic, and endothelial and smooth muscle cells. 5,7 Marked as an innate immunity protein, PTX3 not only regulates inflammatory responses but also is involved in a range of important biological mechanisms, including vascular pathology. In fact, blood vessels produce large amounts of PTX3 during inflammation, and the level of circulating PTX3 increases in several pathological conditions affecting the cardiovascular system. 8, 9 Moreover, in advanced atherosclerotic lesions and in patients with vasculitis, the protein is abundantly present in endothelial cells. 10,11 Thus, PTX3 seems to be a rapid marker of primary local innate immunity and inflammation activation and a novel diagnostic tool for vascular disorders.
chronic kidney disease and preeclampsia, a multisystemic disorder associated with hypertension. [12] [13] [14] Endothelial dysfunction is considered to be an early pathophysiological feature of hypertension, which is strictly associated with increased inflammatory and adhesion molecules in the vascular wall. 8 So far, no studies have reported a possible direct role of inflammatory molecules such as PTX3 on vascular homeostasis or possible involvement in modulation of endothelial function.
Here, we demonstrate that (1) PTX3 induces vascular dysfunction and morphological changes of the endothelial layer in experimental models via an adhesion molecule P-selectin/matrix metalloproteinase (MMP)-1 pathway that converges on nitric oxide (NO) signaling; (2) in vivo PTX3 induces endothelial dysfunction and increases blood pressure in mice; (3) PTX3 impairs NO production through the MMP-1 pathway in human umbilical vein endothelial cells (HUVECs); and (4) PTX3 and its mediators of vascular damage, P-selectin and MMP-1, are elevated in plasma of hypertensive patients.
Methods
For detailed methodology, please see the online-only Data Supplement. In brief, we performed vascular reactivity studies on resistance vessels from C57BL6 mice and from FCγ receptor and P-selectin knockout (KO) mice to evaluate the in vitro vascular effects of PTX3. To test the in vivo effect of PTX3 on blood pressure in mice, we used a polyethylene catheter inserted into a femoral artery. After vascular reactivity, proteins were rapidly extracted from vessels to perform immunoprecipitation and immunoblot studies. Lowtemperature SDS-PAGE was used to evaluate the ratio of endothelial NO synthase (eNOS) dimer and monomer. Morphological analyses and ultrastructural evaluation of caveolin-1 (Cav-1) or MMP-1 localization in mesenteric arteries were performed with transmission electron microscopy. Macroscopic alterations on mesenteric arteries were evaluated with the Evans Blue dye method. HUVECs were used to measured MMP-1 activity through the SensoLyte Plus 520 MMP-1 Assay Kit Fluorimetric and Enhanced Selectivity (Anaspec); NO production was measured with the Sievers 280i NO Analyzer; P-selectin/PTX3 colocalization was evaluated with immunofluorescence analysis; and P-selectin expression was evaluated through flow cytometric analysis. Finally, plasma levels of PTX3, P-selectin, and MMP-1 in hypertensive and normotensive subjects were measured with a high-sensitivity ELISA system for human plasma. The study was approved by an institutional review committee, and the subjects gave their informed consent.
Statistical Analyses
All statistical analyses were performed with Prism (GraphPad). A 2-tailed Student t test was used to calculate statistical significance of Western blot experiments. Data from all experiments are given as mean±SD, except for the vascular reactivity experiments, for which data are given as mean±SEM. Analyses of mean arterial pressure and vascular reactivity curves were performed with the nonparametric Mann-Whitney test. Values of P<0.05 were considered to be significant. The Shapiro-Wilk test was used to evaluate potential deviations of the analyzed quantitative variables of ELISA values from the normal distribution (P<0.05). Quantitative variables following the normal distribution were described by mean±SD or by median (25th-75th percentiles) otherwise. The Welch t test was applied to test for statistically significant difference in terms of normally distributed variables between hypertensive and control subjects. The Wilcoxon rank-sum test was used to test for statistically significant difference in terms of quantitative variables deviating from the normal distribution between hypertensive and control subjects. The roc function implemented in the R package called pROC was used to estimate the area under the receiver-operating characteristic curves and corresponding 95% confidence interval for each variable. The response variable of each model was represented by the hypertensive/control condition, whereas the predictor variables were PTX3, P-selectin, or MMP-1 raw measures. To identify the most informative threshold for each variable to discriminate hypertensive subjects from control subjects, the data set was randomly split into a training set (70% of the whole sample) and a test set (30% of the data) with stratification so that the proportion of cases and controls observed in the whole sample was maintained in the 2 subcohorts. Thus, the most informative thresholds were identified among all the possible values observed on the training set as the ones guaranteeing the highest Matthews correlation coefficient, which is the most appropriate parameter for the analysis of data sets characterized by unbalanced outcomes. The discriminative performances of the analyzed variables discretized according to the identified thresholds were assessed on the independent training and test set in terms of Matthews correlation coefficient, sensitivity, specificity, positive predictive value, negative predictive value, and F measure. Statistical tests were performed by R software version 3.1.0 (www.r-project.org/).
Results

PTX3 Induces Endothelial Dysfunction in Mouse Resistance Vessels
Elevated levels of PTX3 have been associated with endothelial dysfunction in humans. [12] [13] [14] [15] Therefore, we evaluated whether the protein was able to influence endothelial function, which is impaired in hypertension. 16 To this end, we tested the effects of increasing doses of PTX3 (2, 20, and 200 ng/mL) for different preincubation times (15, 30, 45 , and 60 minutes) on acetylcholine-evoked endothelial vasorelaxation of preconstricted mouse mesenteric vessels ( Figure 1 ). We found that 2 ng PTX3/mL did not influence endothelial function ( Figure 1A ). In contrast, 20 ng/ mL induced a significant reduction in acetylcholine-evoked vasorelaxation after 45 minutes of preincubation; the effect was similar to that observed after 60 minutes ( Figure 1B) . The endothelial vasorelaxation observed in the presence of 200 ng PTX3/mL ( Figure 1C ) was not statistically different from that evoked by 20 ng/mL. Thus, we decided to use 20 ng/mL for 45 minutes of preincubation in all subsequent in vitro experiments.
To understand whether the vascular action of PTX3 on the endothelium was generalized or specific for a vascular district, we tested its effect on other vascular beds such as femoral arteries and aorta. PTX3 induced endothelial dysfunction of the femoral artery ( Figure Ia in the online-only Data Supplement) but not of the windkessel such as aorta ( Figure Ib in the online-only Data Supplement). Moreover, the vascular action of PTX3 was specific for endothelial function because nitroglycerine-evoked relaxation of smooth muscle was not influenced (data not shown).
Fluorescence immunostaining with exogenous biotinylated PTX3 clearly showed that the protein was endothelially localized, as evidenced by the specific interaction between biotin and fluorescent streptavidin ( Figure 1D ). Of note, it was not observed in the aorta, in which PTX3 failed to exert any vascular effect (Figure Ic in the online-only Data Supplement). Taken together, these findings demonstrate that the target of the vascular action of PTX3 is the endothelium and that it induces dysfunction of resistance vessels. 
P-Selectin Mediates the Action of PTX3 on the Endothelium
In the immunology field, P-selectin and the Fcγ receptor have been identified as 2 receptors of PTX3, 17, 18 but there are no data on the involvement of such receptor(s) at the vascular level. To clarify this issue, we performed experiments on mesenteric arteries from P-selectin and FCγ receptor KO mice, testing the endothelial vascular effect of PTX3. Vascular reactivity studies demonstrated that PTX3 blunted acetylcholine-evoked vasorelaxation in FCγ receptor KO vessels ( Figure 2A ) but failed to exert any effect in P-selectin-deficient ones ( Figure 2B ). These results indicated P-selectin as the cognate receptor of PTX3 in endothelial cells. In agreement, P-selectin immunoprecipitated with PTX3 in wild-type (WT) mesenteric artery lysates. As expected, P-selectin could not be immunoprecipitated from P-selectin KO mice ( Figure 2C ).
In addition to PTX3, P-selectin interacts with serum amyloid protein in immunological 19 and vascular processes. Figure 1 . A through C, Dose-response curves to acetylcholine (Ach) of phenylephrine-precontracted mesenteric arteries from C57BL/6N mice. Vessels were pre-exposed to pentraxin 3 (PTX3) for 15, 30, 45, or 60 minutes at different doses (2, 20, or 200 ng/mL). **P<0.01, ***P<0.001 vs vehicle, 15 minutes, and 30 minutes; n=7 for each group. D, Immunohistochemical staining with fluorescent streptavidin of mesenteric arteries from C57BL/6N mice treated with vehicle or with biotinylated PTX3. Scale bar, 100 μm. Figure 2 . A, Dose-response curves to acetylcholine (Ach) of phenylephrineprecontracted Fcγ +/+ and Fcγ −/− mesenteric arteries exposed to vehicle or pentraxin 3 (PTX3) for 45 minutes. *P<0.05, **P<0.01 vs FCγ −/− +vehicle and FCγ +/+ +vehicle; n=5 for each group. B, Dose-response curves to Ach of phenylephrine-precontracted P-selectin +/+ and P-selectin −/− mesenteric arteries after 45 minutes of exposure to vehicle or PTX3. *P<0.05, **P<0.01 vs P-selectin −/− +vehicle, P-selectin −/− + PTX3, and P-selectin +/+ +vehicle; n=5 for each group. C, Endogenous P-selectin immunoprecipitated with PTX3 in mesenteric artery lysate from wild-type (WT) but not from P-selectin knockout (KO) mice. Extracts were immunoprecipitated for P-selectin and then probed with anti-P-selectin or anti-PTX3 antibodies; n=3.
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We found that serum amyloid protein-evoked endothelial dysfunction failed to exert an effect on P-selectin KO mice (Figure IIa in the online-only Data Supplement). This action is not common to other inflammatory factors such as C-reactive protein that induce endothelial dysfunction through interaction with the FCγIIB receptor. 20 In agreement, C-reactive protein was still able to induce its vascular effect in P-selectin KO mice ( Figure IIb in the online-only Data Supplement).
PTX3-Evoked Endothelial Dysfunction Is Associated With Morphological Changes in Endothelial Cells
An interesting observation emerging from vascular reactivity studies was that endothelial dysfunction was still present after continuous washout of PTX3 from the organ bath housing the vessels ( Figure 3A ). This finding led us to hypothesize that PTX3 induced a morphological alteration. We therefore studied mesenteric arteries at the ultrastructural level to see whether treatment with PTX3 could induce phenotypic alterations in vascular cells. WT vessels treated with vehicle had a normal architecture with typical indented nuclei, well-organized cytoplasm, and intact plasma membrane ( Figure 3B1 ). In contrast, PTX3 induced the presence of large vacuoles, a diluted cytoplasm, and a broken plasma membrane ( Figure 3B2 ). Of note, no structural alterations were detected in P-selectin −/− mesenteric endothelial cells after exposure to vehicle or PTX3 ( Figure 3B3 and 3B4); moreover, no structural changes were seen in the smooth muscle layer after exposure to PTX3 (data not shown). In agreement, Evans Blue dye staining, which identifies vascular leakage, was acquired only by PTX3-treated vessels (additional data are provided in the Results section and Figure III in the online-only Data Supplement).
PTX3-Induced Vascular Morphological Changes Are Mediated by a P-Selectin/MMP-1 Pathway
On the basis of the results of the ultrastructural analysis of mesenteric arteries, we focused our attention on the identification of the mediators of the morphological alterations induced by PTX3, exploring the involvement of important molecules recruited in vascular structural changes, namely MMPs. We first evaluated the effect of PTX3 on endothelial function in the presence of GM6001, an inhibitor of MMP-1, -2, -3, -8, and -9. In agreement with our hypothesis, this nonselective MMP inhibitor protected mesenteric arteries against the endothelial dysfunction promoted by PTX3 ( Figure 4A ). We then set out to identify the specific MMP involved, using siRNA to selectively silence the expression of MMP-1 and MMP-9, which are highly present MMPs in the endothelial layer. We found that silencing of MMP-9 did not alter the vascular effects of PTX3 ( Figure 4B ); in contrast, silencing MMP-1 protected against PTX3-evoked endothelial dysfunction ( Figure 4C ). In agreement, Western blotting revealed that PTX3 enhanced MMP-1 expression in WT mouse mesenteric artery ( Figure 4D ), an effect absent in P-selectin −/− vessels ( Figure 4E ), and that PTX3-induced ultrastructural alterations were absent in vessels transfected with MMP-1 siRNA ( Figure 4F ). Taken together, these findings clearly demonstrate the involvement of a P-selectin/ MMP-1 pathway in PTX3-induced damage to the membrane of endothelial cells.
PTX3 Alters NO Signaling
NO is the main determinant of the vasorelaxant effects mediated by endothelium. 21 Our data showing selective impairment of the endothelial layer after exposure to PTX3 prompted us to explore its effect on NO signaling. In particular, we found that PTX3 blunted phosphorylation of eNOS at serine 1177, an activation site of the enzyme ( Figure 5A ), and uncoupled eNOS, as evidenced by the increase in the monomeric form ( Figure 5B) .
At the function level, l-N G -nitro arginine methyl ester (L-NAME)-induced eNOS inhibition significantly blunted the acetylcholine response in control vessels, indicating the presence of NO in the vasorelaxant action of acetylcholine ( Figure IVa , top, in the online-only Data Supplement). In Figure 3 . A, Dose-response curves to acetylcholine (Ach) of phenylephrineprecontracted mesenteric arteries from C57BL/6N mice (WT); vessels were untreated, exposed to pentraxin 3 (PTX3) for 45 minutes (WT+PTX3), or exposed to PTX3 with continuous washout (WT+PTX3 washout). **P<0.01 vs WT; ##P<0.01 vs WT; n=6 for each group. B, Effect of PTX3 on the ultrastructure of endothelial cells. Representative micrographs of endothelial cells from WT and P-selectin knockout (KO) mice under basal conditions (1 and 3) or after exposure to PTX3 (2 and 4). WT and P-selectin KO endothelial cells under basal conditions and P-selectin KO endothelial cells exposed to PTX3 had well-preserved cytoplasm (C) and nuclei (N); WT mesenteric artery endothelial cells exposed to PTX3 had a dilution of the cytoplasm and disruption of the plasma membrane (arrows); n=4 for each group. Scale bars, 1.17 μm (1) and 0.76 μm (2). V indicates vacuole. P-selectin KO mice were protected against the effect of PTX3 on NO signaling ( Figure 5C ).
A comparable effect on eNOS phosphorylation was observed with the use of serum amyloid protein, which has been reported to act via the P-selectin receptor 19 (additional data are given in the Results section and Figure V in the online-only Data Supplement).
NO plays a crucial role in the modulation of vascular tone, counteracting smooth muscle vasoconstriction. 22 Accordingly, we observed that the inhibition of eNOS obtained with L-NAME enhanced smooth muscle phenylephrine-evoked vasoconstriction in control vessels ( Figure IVb Figure 5D , bottom). These data clearly demonstrate that the greater smooth muscle contraction observed in PTX-treated vessels is dependent on an impairment of NO signaling.
Finally, recruitment of macrophages, which may play a role in vasoconstriction, 23 was not detected in vessel walls after PTX3 administration (additional data in the Results section and Figure VI in the online-only Data Supplement). Figure 4 . A, Dose-response curves to acetylcholine (Ach) of phenylephrine-precontracted mesenteric arteries from C57BL/6N mice. Vessels were exposed to vehicle only, to pentraxin 3 (PTX3) for 45 minutes (PTX3), to GM6001+PTX3 (GM6001+PTX3), or to GM6001 alone (n=6 for each group). *P<0.05 vs vehicle, GM6001+PTX3, GM6001; **P<0.01 vs vehicle, GM6001+PTX3, GM6001. B and C, Doseresponse curves to Ach of phenylephrine-precontracted mesenteric arteries from C57BL/6N mice. Vessels were exposed to vehicle or transfected with siRNA against matrix metalloproteinase (MMP)-9 (**P<0.01 vs vehicle, scrambled siRNA; ##P<0.01 vs vehicle, scrambled siRNA) or MMP-1 and then exposed to PTX3; scrambled siRNA was used as a control. **P<0.01 vs vehicle, scrambled siRNA, and siRNA MMP-1+PTX3; n=8 for each group. D, Representative Western blots for MMP-1 in wild-type (WT) mesenteric arteries exposed to vehicle, PTX3, siRNA to silence MMP-1, or scrambled siRNA (n=3). *P<0.05, **P<0.01. E, Representative Western blots for MMP-1 in mesenteric arteries from WT and P-selectin −/− vessels exposed to vehicle or PTX3 (n=3). **P<0.01. F, Effect of silencing MMP-1 on the ultrastructural alterations induced by PTX3: (1) Control endothelial cells had well-preserved cytoplasm (C) and nucleus (N); (2) cells exposed to PTX3 had diluted cytoplasm with numerous vacuoles (arrows) and broken membranes (thick arrow); and (3) silencing of MMP-1 with an siRNA inhibited PTX3-induced changes. Scale bar, 1.1 μm (n=4 for each group). 
PTX3 Evokes the Detachment of Cav-1 From Plasma Membrane
We performed further analysis aimed at understanding how the morphological changes correlated with impairment of endothelial signaling. Ultrastructural analyses revealed that endothelial cells from mesenteric arteries of WT mice treated with vehicle or from mice treated with siRNA targeting MMP-1 had a well-preserved architecture and vesicles (caveolae) under the plasma membrane ( Figure 5E1 ). These caveolae presented as uncoated vesicles organized in clusters forming a complicated network just below the plasma membrane ( Figure 5E1 and 5E3). Moreover, these vesicles were delimited by a membrane that was continuous with the plasma membrane ( Figure 5E3 ). The ultrastructural features of the caveolae were in line with what was observed by Rajamannan and coworkers 24 in their detailed transmission electron microscopy study on endothelial cells. After exposure to PTX3, endothelial cells presented with disruption of the plasma membrane, and Cav-1 immunogold particles were found relocated to poorly preserved vesicles within intracellular cytoplasmic regions ( Figure 5E2 ).
When mesenteric artery endothelial cells from control and siRNA-MMP-1-treated WT mice were processed for MMP-1 immunocytochemistry, the gold particles were found located in vesicles under the plasma membrane ( Figure 5E4 ) and in vesicles continuous with the plasma membrane ( Figure 5E6 ). After exposure to PTX3, endothelial cells had a great number of MMP-1 gold particles located inside the cells ( Figure 5E5 , top); moreover, particles were located on the plasma membrane and on vesicles under it ( Figure 5E5, bottom) .
Finally, immunoprecipitation studies revealed that eNOS remained linked to Cav-1 in PTX3-treated vessels ( Figure 5F ). The silencing of MMP-1 via siRNA protected against plasma membrane disruption and rescued eNOS detachment from Cav-1 ( Figure 5F ). in control conditions (alone) or in the presence of PTX3 or PTX3+l-N G -nitroarginine methyl ester (L-NAME; 300 µmol/L). **P<0.01 vs WT; n=5 for each group. E, 1, Endothelial cells from WT mesenteric artery had anti-caveolin-1 (CAV-1) immunogold particles (arrows) located in short spherical vesicles (caveolae) under the plasma membrane. 2, After exposure to PTX3, endothelial cells had a disrupted plasma membrane (asterisk), and anti-CAV-1 immunogold particles (thick arrows) was distributed under the plasma membrane in poorly preserved vesicles. 3, Endothelial cell of a WT siRNA matrix metalloproteinase (MMP)-1 mesenteric artery with anti-CAV-1 immunogold particles staining a vesicle under the plasma membrane. Arrowheads point to the membrane delimiting the vesicles. The thin arrow points to an immunogold particle located outside the endothelial membrane in the vessel lumen. Scale bar, 0.182 µm (A), 0.17 µm (B), and 0.167 µm (C). 4, Mesenteric artery endothelial cell from a WT mouse with a cluster of anti-MMP-1 immunogold particles located in vesicles under the plasma membrane (arrows). 5, Top, After exposure to PTX3, endothelial cells had a greater number of anti-MMP-1 gold particles located inside the cells, on the plasma membrane, and on vesicles under the plasma membrane (bottom; arrows). 6, Endothelial cells from siRNA MMP-1 mice showing MMP-1 immunogold particles located in vesicles continuous with the plasma membrane (arrows); n=3 for each experimental condition. F, Endogenous eNOS immunoprecipitated with CAV-1 in mesenteric artery lysate from C57BL/6N. Vessels were exposed to vehicle alone or to PTX3 alone or were transfected with siRNA MMP-1 and exposed to PTX3. Extracts were immunoprecipitated for CAV-1 and then probed with anti-eNOS or anti-CAV-1 antibodies; n=3. 
In Vivo Effects of PTX3 on Vascular Function and Blood Pressure
Endothelial dysfunction is a typical marker of arterial hypertension. 8 Our in vitro findings therefore prompted us to explore the effects of PTX3 on blood pressure and vascular function in vivo. To this end, we injected mice with PTX3 or vehicle and evaluated blood pressure in a time period previously reported to be sufficient for effects to appear in vivo. 18 We found that administration of the protein significantly increased the blood pressure of WT mice ( Figure 6A and Figure VIIa in the onlineonly Data Supplement), an effect counteracted by the absence of P-selectin ( Figure 6B and Figure VIIb in the online-only Data Supplement). In addition, when we excised vessels for vascular reactivity studies and ultrastructural analysis, we observed endothelial dysfunction ( Figure 6C ) and morphological changes ( Figure 6D2 ) similar to those encountered in the ex vivo experiments. As expected, administration of PTX3 did not evoke vascular effects in P-selectin KO mice ( Figure 6C and Figure 6D4 ).
No significant differences were observed between mice with a genetic ablation of PTX3 and their controls ( Figure  VIIc in the online-only Data Supplement), suggesting that the absence of PTX3 does not influence blood pressure levels under basal conditions.
PTX3 Impairs NO Production in HUVECs
Data obtained in vessels demonstrated that the endothelium is the target of the vascular action of PTX3. Thus, we focalized our attention on HUVECs. We found that PTX3 impaired NO production in HUVECs through an involvement of the MMP-1 signaling pathway (additional data are given in the Results section and Figures VIII and IX in the online-only Data Supplement).
Hypertensive Patients Have Elevated Plasma Levels of PTX3, P-Selectin, and MMP-1
The findings from our experimental models indicated that P-selectin and MMP-1 mediated the vascular effects of PTX3, including the increase in blood pressure. To corroborate this finding in humans, we measured the plasma levels of PTX3, P-selectin, and MMP-1 in 31 hypertensive patients taking antihypertensive medication but who did not have good blood pressure control, as well as in a group of subjects who were not on antihypertensive medication and had normal systolic and diastolic blood pressures (Table) . We found that hypertensive patients had significantly higher plasma concentrations of PTX3, P-selectin, and MMP-1 compared with normotensive subjects. ( Figure 7A and Table) . In particular, the PTX3 value reached the highest accuracy as shown by the area under the receiver-operating characteristic curve compared with other variables ( Figure 7B ; additional data are provided in the Results section and Tables I and II in the online-only Data Supplement).
Discussion
We report here for the first time the direct role of PTX3 on vascular endothelial function, identifying the molecular mechanisms involved. In particular, we demonstrate that PTX3 induces endothelial dysfunction in resistance vessels, a district involved in the modulation of blood pressure level, and we show that the protein localizes to the endothelial monolayer, suggesting a possible interaction with a receptor.
So far, the presence of a PTX3 receptor has been reported for inflammatory cells, in which PTX3 interacts either with the Fcγ receptor to amplify innate resistance against pathogens 18 or with P-selectin in a negative feedback loop to prevent excessive recruitment of neutrophils. 19 Here, we demonstrate that P-selectin is the cognate PTX3 receptor on vascular cells because vessels from P-selectin KO mice were refractive to PTX3-evoked endothelial dysfunction, whereas those from FCγ receptor KO mice were not. It is important to emphasize that P-selectin is both a receptor and an adhesion molecule stored within the α-granules of platelets and the Weibel-Palade bodies of endothelial cells, in which it is located on membranes at a low concentration also in the http://circ.ahajournals.org/ basal condition. 25, 26 We also demonstrate that PTX3 induces an increase in P-selectin on the membrane of isolated endothelial cells.
An interesting observation emerging from our study is that endothelial dysfunction is still present after the removal of PTX3. This led us to hypothesize a mechanism that induced changes in vascular structure. In fact, ultrastructural analysis of the endothelial layer of vessels revealed extensive vacuolization of the cytoplasm and disruption of basal membranes after exposure to PTX3. These findings are in agreement with a previous study showing the ability of the PTX family to induce membrane disruption in Gram-negative bacteria. 27 The morphological alterations seen in the endothelial cells were completely absent at the muscular level, pointing to the endothelium as the specific target of PTX3. The absence of P-selectin protected against PTX3-mediated morphological changes and vascular dysfunction, leading us to hypothesize that the structural alterations contributed to endothelial dysfunction.
The main mechanism related to endothelial dysfunction in hypertension is represented by alteration of the NO pathway. 28, 29 On this point, our studies revealed that PTX3 induced an impairment in NO signaling that evoked endothelial dysfunction and enhanced smooth muscle vasoconstriction, 2 typical traits involved in increased vascular resistance in hypertension. 22 We also aimed to understand how the morphological changes observed in our study correlated with the impairment in endothelial signaling. In endothelial cells, it is known that eNOS is targeted mostly to caveolae on the plasma membrane through interaction with Cav-1, 30 the major protein constituent of this membrane microdomain caveolae. 31 Binding to eNOS negatively regulates the activity of the enzyme, maintaining eNOS in the monomeric state. 32 In vessels treated with PTX3, we found that, after disruption of the plasma membrane, Cav-1 relocated to intracellular cytoplasmic regions and remained linked to eNOS, as evidenced by immunoprecipitation studies. This condition was associated with the presence of eNOS in its monomeric state, clearly indicative of inactivated NO intracellular signaling.
It was previously reported that the absence of PTX3 is accompanied by greatly diminished tissue inflammation and injury and decreased lethality after reperfusion of an ischemic superior mesenteric artery in mice, demonstrating that PTX3 is relevant to tissue damage. 33, 34 In agreement, PTX3overexpressing mice had greater tissue damage and mortality after reperfusion of the ischemic vascular bed. 35 Our finding that PTX3 is harmful for the mesenteric district is fully in agreement with previous reports suggesting that therapeutic blockade of the action of PTX3 may be useful for injuries associated with severe ischemia and reperfusion syndromes in the this area. 35 We also identify signaling molecules recruited by the PTX3/P-selectin pathway to induce the vascular changes. Among the possible candidates, metalloproteinases play a prominent role. This is an expanding family of endopeptidases with the ability to degrade extracellular matrix components and to digest the endothelial basal lamina. 36 In addition, MMPs are inflammatory mediators linking inflammation with angiogenesis and vascular remodeling, and they are implicated in the pathogenesis of vascular diseases such as atherosclerosis, aortic aneurysms, plaque rupture, and neointimal hyperplasia. 37 We demonstrate that nonselective inhibition of MMP with GM6001 protected against PTX3-evoked vascular damage. The major MMP isoforms expressed in the vasculature include MMP-1, -2, -3, and -9; among these, MMP-1 is secreted predominantly by endothelial cells 38,39 and has been reported to be associated with organ damage during arterial hypertension. 40 We demonstrate for the first time that PTX3 increases MMP-1 expression in resistance vessels. The evidence showing that this effect is absent in P-selectin −/− vessels clearly demonstrates that MMP-1 is a downstream member of the PTX3/P-selectin pathway. To definitively demonstrate the involvement of MMP-1 in PTX3-mediated vascular changes, we silenced it with siRNA. In this experimental setting, PTX3 failed to promote endothelial NO dysfunction and morphological vascular alterations, including Cav-1 relocation from the plasma membrane.
Our data clearly propose the endothelium as the target of the vascular action of PTX3. We focalized our attention on isolated HUVECs to specifically evaluate the effect of PTX3 on NO production. We demonstrate for the first time that PTX3 reduces NO production in isolated endothelial cells and that this effect is associated with an enhanced expression and activity of MMP-1. The silencing of MMP-1 by siRNA protected against the deleterious action of PTX3 on NO.
We also characterized the effect of PTX3 in vivo by injecting the protein intraperitoneally at a dose already reported to modulate P-selectin-mediated inflammatory response. 18 In this experimental setting, PTX3 also induced endothelial dysfunction, vascular morphological changes, and an increase in MMP-1 expression. Lack of P-selectin protected the vascular system against the harmful effects of PTX3. Of note, in vivo administration was not accompanied by reductions in neutrophil accumulation and an inflammatory status, suggesting that the effect observed did not depend on the inflammatory system. 18 It is important to emphasize that our in vivo findings are similar to those obtained in vitro, a setting that cannot be influenced by systemic inflammatory responses.
The transgenic PTX3-overexpressing mouse is an experimental model characterized by the presence of higher PTX3 levels than normal. A careful analysis of data revealed that overexpression of the protein is induced by different stimuli. 33, 35 So far, there are no available data on blood pressure in this experimental condition, and future studies will need to pursue this goal.
Endothelial dysfunction is a typical marker of several cardiovascular disorders such as arterial hypertension. It is still debated whether endothelial dysfunction participates in hypertension or is evoked by high blood pressure. Our in vivo experiments demonstrate that PTX3 significantly increases blood pressure in our observation period and that this hemodynamic effect was mediated by P-selectin. In vitro experiments demonstrated that PTX3 induces endothelial dysfunction in an experimental condition not influenced by high pressure levels. Thus, taken together, our results suggest that endothelial dysfunction induced by PTX3 participates in the increase in blood pressure observed after in vivo administration of the protein.
In addition to PTX3, other inflammatory factors are able to induce vascular dysfunction.
Interestingly, serum amyloid protein interacts with P-selectin in immunological processes and induces endothelial dysfunction via the same receptor at the vascular level. However, P-selectin does not represent the common target of all inflammatory factors because C-reactive protein evokes its deleterious vascular effect through interaction with the FCγIIB receptor. 20 Thus, these inflammatory molecules recruit different mechanisms for their vascular effects; their characterization could help to better define their roles in the clinical setting.
Finally, we found that the plasma levels of P-selectin and MMP-1, 2 mediators of the vascular damaging effects of PTX3, are higher in hypertensive patients. Our data are supported by previous studies reporting an association of elevated plasma P-selectin with hypertension 41,42 and by a study in which MMP-1 was associated with organ damage and progression of hypertension. 40 In conclusion, we describe for the first time the direct involvement of the acute-phase protein PTX3 in cardiovascular homeostasis, with the modulation of vascular function and blood pressure in experimental models. Data obtained in humans suggest that PTX3, P-selectin, and MMP-1 may represent new biomarkers for the prediction of vascular dysfunction onset in hypertensive patients. These biomarkers are closely linked because P-selectin and MMP-1 are downstream molecules of the signaling pathway initiated by PTX3. Thus, the monitoring of these proteins could become part of a novel preventive strategy aimed at blunting the evolution of high blood pressure.
Study Limitations
We analyzed only a short time window of the effects of PTX3 on vascular function and blood pressure homeostasis. This decision was based on a previous study reporting that 2 hours was enough to evoke effects induced by PTX3 in vivo. 19 More studies are therefore warranted to fully characterize the action of PTX3 on cardiovascular homeostasis over a longer period. Nevertheless, the effects observed in this short time frame were sufficient for us to define the molecular mechanisms involved. In addition, the hypertensive patients studied were receiving 
CLINICAL PERSPECTIVE
Several studies have proposed pentraxin 3 as a potential therapeutic tool for chronic lung infections because it is able to reduce lung colonization, proinflammatory cytokine levels, and leukocyte recruitment in the airway. Its possible therapeutic action has also been reported in chronic granulomatous disease, in which it exerts an anti-inflammatory effect. Our study has disclosed the harmful vascular effect evoked by pentraxin 3 and the recruited molecular mechanisms, which could help better define its role in the clinic. In particular, our data highlight novel targets for future therapeutic strategies aimed at selectively blocking the molecules triggered by the protein in the vessel without affecting other actions in the different districts. Animals. Fcγ-R-and P-selectin-deficient mice were obtained from Instituto Humanitas. Procedures involving animals and their care conformed to institutional guidelines. All effort was made to minimize the number of animals used and their suffering.
Vascular reactivity study. Second-order branches of the mesenteric arterial tree were removed from C57BL6 mice and from FCγR-and P-selectin-knock-out mice for vascular studies performed as described previously 2 . Briefly, vessels were placed in a wire or pressure myograph system filled with Krebs solution maintained at pH 7.4 at 37°C. Adventitial fat was carefully removed and arteries were cut into rings (̴ 2-mm thickness). The rings were suspended by two tungsten wires (25µm in diameter) and mounted with 0.3 g of resting tension in a wire myograph system (5-mL chamber size; DMT Danish Myosystem). Isometric tension was measured using a force transducer coupled to a data acquisition system. After an equilibration period of 60 minutes, rings were precontracted with phenylephrine (1 ×10 -9 to 10 -5 M) until a plateau was reached. Vessels were then washed, and this was repeated at least three times in order to stabilize the tissue. Endotheliumdependent and -independent relaxations were assessed by measuring the dilatory response of mesenteric arteries to cumulative concentrations of acetylcholine (from 10 -9 M to 10 -5 M) or nitroglycerine (from 10 -9 M to 10 -5 M), respectively, in vessels pre-contracted with phenylephrine at a dose necessary to obtained a similar level of pre-contraction in each ring (80% of initial KClevoked contraction). Some mesenteric arteries mounted on a pressure myograph were transfected with 20 μg of MMP-1 siRNA or with scrambled siRNA. In particular , siRNA was diluted into 200
mL Opti-MEM I. An equal volume of PLUS reagent was added. The mixture was incubated for 5 min. Lipofectamine LTX was added, and the complexes were allowed to form by incubation for 25 minutes 3 . Subsequently, 200 mL of complex were injected into P1-way (into vessel) of pressure myograph and then vessels were perfused at 100 mmHg for 1 hour and then at 60 mmHg for 5 hours as previously described 3 .
Blood pressure Measurement
Two days before testing PTX3 on blood pressure, mice were anesthetized with 0.03 mL of a 2:1 mixture of ketamine (100 mg/mL IM, Aveco Co) and xylazine (20 mg/mL IM, Miles Inc) and
placed on an operating surface maintained at 38°C. A polyethylene catheter (PE-10; Becton Dickinson, Sparks) was inserted into a femoral artery as previously described 4 .
The surgery was performed in a uniform fashion by a single investigator (A.D.) between 8 AM and noon. The catheter was filled with heparinized saline solution (100 μU/ml) and exteriorized subcutaneously at the interscapular area. It was connected to a pressure transducer (WPI, TBM4M) and arterial blood pressure was monitored and recorded on a computer system (WPI, Trans Bridge 4M). After surgery, mice were individually housed in cages and allowed to recover. Direct intrafemoral arterial pressure was measured in conscious, freely moving mice after an overnight fast as previously described 4 .
Intra-arterial blood pressure was evaluated in WT and P-selectin KO mice under basal conditions and after PTX3 injection (100µg, intraperitoneally). Mice used as controls were treated in a similar way, but with PTX3 substituted with the vehicle alone. Basal blood pressure was evaluated also in WT and PTX3 KO mice for one week. At the end of blood pressure measurements, some vessels were excised for vascular reactivity, western blot or morphological analyses.
Immunoprecipitation. Mesenteric artery homogenates were prepared in 5 mM Tris-HCl buffer, pH 7.5, containing 1 mM CaCl 2 , 1 mM MgCl 2 , and 1 mM NaHCO 3 . Samples containing 1 mg of total protein were lysed for 40 min at +4°C with lysis buffer at pH 7.5 containing 50 mM Tris-HCl, 150
mM NaCl, 1% NP-40, 1 mM Na 2 P 2 O 7 , 1 mM NaF, 1 mM EDTA, 2 mM NaVO 4 , 0.1 mM PMSF, and complete protease inhibitor cocktail (Roche), and centrifuged for 15 min at 20,000 g at 4°C.
Supernatants were cleared with protein A/G-agarose beads (Santa Cruz Biotechnology, Inc.) for 2 hours at 4° and incubated or with anti P-selectin or with anti-Caveolin-1 antibody, followed by precipitation with protein A/G-agarose beads for 1 hour at 4°C. The beads were washed three times with lysis buffer and two times with PBS, and then analyzed by immunoblotting. Low temperature SDS-PAGE.
Low-temperature SDS-PAGE (LT-PAGE) was performed for detection of SDS-resistant eNOS dimer and monomer, as described previously 5 .
Cell cultures. HUVEC (Lonza) were cultured in EBM-2 media (Lonza). HUVEC were cultured at 37°C in 5% CO 2 /95% air by standard methodologies in 25-cm 2 T tissue culture flasks (50 ml capacity) (Falcon, Becton Dickinson Labware) in the presence of endothelial cell growth supplement. In general, HUVEC were used for our experiments after 3-5 passages. For starvation experiments, serum-and growth factor-free medium was used. For siRNA-mediated gene knockdown, HUVECs were grown to 60% to 70% confluence and transfected with Lipofectamine LTX (Invitrogen) according to the protocol of the manufacturer. As control, a scrambled-RNA was used. 24 h after siRNA transfection, cells were washed with PBS and then left for 2h in serum-and growth factor-free medium before of each treatment.
Measurement of MMP-1 activity.
HUVEC were cultured at 37°C in 5% CO2/95% air by standard methodologies in 100 mm dishes to achieve 70-80% of confluence. Treatment with PTX3 (2 and 20 ng/mL) and P-Selectin (50 and 100 ng/mL) was performed in serum-and growth factor-free medium. Cells were treated for 1 hour; at the end of treatments, medium was collected and concentrated 10X using Ultra-Amicon 10K 
Measurement of NO
Total NO content in the supernatants of HUVEC cultures was measured in an additional experiment. Cells were grown in 100mm dishes and supernatants collected after stimulation with acetylcholine (100 µM for 20 minutes), used to induce NO production. In some experiments, cells were pretreated with PTX3 (20ng/mL) or with siRNA MMP1 plus PTX3 (20ng/mL). The nitric oxide concentrations in the supernatant was assayed as nitrite, the stable breakdown product of NO, by a chemiluminescence detector (Sievers 280i NO Analyzer), as previously described 6 . For immunocytochemistry, mesenteric arteries were processed as described for plain TEM.
Post-embedding immunoelectron microscopy was performed. Ultra-thin sections (50 nm) were deosmicated with aqueous solution of sodium metaperiodate and incubated for 24 h at 4°C with primary antibodies against CAV-1 or MMP1 (Sigma-Aldrich) diluted 1:10 in PBS containing 0.2% saponin (Sigma) and 1% normal goat serum. Then, sections were incubated with gold-conjugated secondary antibodies (20-nm gold particles) diluted 1:10 in buffer solution for 1 h at 25°C. Finally, sections were fixed with 1% glutaraldehyde, stained with uranyl acetate and lead citrate, and examined under a Jeol JEM SX 100 electron microscope. Control sections were obtained by omitting the primary antibody and incubating with only the secondary antibody.
Evans blue Dye
Vascular structure alterations on mesenteric arteries were assessed also using Evans Blue Dye (Sigma) according to the method previously described with minor modification 7 . Briefly, 50 mL of solution containing 2% Evans blue diluted in saline was injected into the tail vein 10 minutes before euthanasia, followed by fixation with a perfusion of 4% paraformaldehyde for 10 minutes. Images were captured with an LSM 510 microscope (Carl Zeiss MicroImaging).
Immunofluorescence analysis.
On vessels:
Mesenteric arteries were treated with biotinylated PTX3 (20ng/mL) for 45 minutes and then cryopreserved in killik medium (Bioptica). Vessels were then processed in a cryostat to obtain 10µm sections disposed on polarized slides (Carlo Erba). Sections were then extensively washed and treated with fluorescence streptavidin (1:500) and incubated for 2 hours at room temperature.
Different sections of mesenteric arteries from WT and P-selectin KO mice were processed with different primary antibodies (CD31, a-SMA) to evaluate the integrity of endothelial or smooth muscular layer, and then with respective secondary antibodies. Finally, the sections were visualized with a Zeiss 2 fluorescence microscope.
Another experimental series of vessels was processed for immunohistochemical staining on Blood pressure (BP) was measured with the patient seated with the use of a validated automatic device. Three consecutive readings were recorded, and the mean was used for the analysis.
Characteristics of the patients are given in Table 1 .
Venous blood was collected in EDTA vacuum containers and stored at −80°C. PTX3, Pselectin and MMP-1 were then measured using a high-sensitivity, enzyme-linked immunosorbent assay (ELISA) system for human plasma. Preparation of plates and sandwich ELISA were performed according to the manufacturers' instructions for each specific kit (PTX3 Human ELISA Kit, Abnova # KA1007; CD62P P-Selectin Human ELISA Kit, abcam # ab100631; MMP1 Human ELISA Kit, abcam # ab100603).
Supplemental Results
Macroscopic evaluation of PTX3-evoked vascular changes
Our data demonstrate that the target of PTX3's vascular action is the endothelium and that it induces dysfunction of resistance vessels. To further support this data, macroscopic images of changes in vascular structure were assessed using Evans Blue Dye (EBD) staining and immunohistochemistry using labeled markers for endothelium and smooth muscle (CD31, a-SMA).
We found that only PTX3-treated vessels acquired EBD (Fig. S3a) and showed a significant reduction of CD31, indicating a specific alteration of the endothelial layer, since no differences were observed in the smooth muscle marker (Fig. S3b) .
SAP induces an impairment of eNOS phosphorylation
Considering the endothelial dysfunction induced by SAP at the vascular level, we performed Western blotting on resistance vessels from WT and P-selectin deficient mice exposed to SAP, to evaluate the phosphorylation status of eNOS. Interestingly, the impairment of eNOS phosphorylation evidenced in vessels from WT mice was absent in P-selectin knockout mice ( Fig   S5) . These data were coherent with the results on vascular reactivity.
PTX3-evoked vascular damage is not associated with macrophage recruitment
We studied the possible recruitment of immune cells in vessels from WT and P-selectin KO mice treated with PTX3. Our histologic and immunohistochemistry analyses clearly demonstrate that in both WT and P-selectin KO mice treated with PTX3, there was no positivity for F4-80, an extensively used marker for macrophage cells, compared to positive control vessels treated with LPS, in which each sections showed a well-marked cell. We conclude that PTX3-evoked vascular action is not associated with a recruitment of macrophages to the vessel wall ( Fig. S6 ).
Effect of PTX3 on HUVEC a) Effect of PTX3 on P-selectin expression
Confocal microscopy revealed that treatment with PTX3 (20ng/mL for 0-60 minutes) induced expression of P-selectin on cell membranes (Fig. S8a) . To confirm this, we performed flow cytometry experiments, finding that exposure to exogenous PTX3 up-regulated P-selectin expression in HUVEC, as indicated by a rightward shift in the output curve (increased percentage of positive cells and higher mean fluoresce intensity) ( Fig. S8b) .
b) Effect of PTX3 on NO production
Western blotting revealed a significant increase of MMP-1 expression in cells treated with PTX3 ( Fig. S9a ). In addition, spectrofluorimetry detected a significant increase in MMP-1 activity (Fig.   S9b ). As observed at the vascular level, PTX3 impaired NO signaling also in isolated endothelial cells, as evidenced by reduced dimerization of eNOS and phosphorylation on serine 1177 ( Fig.   S9c ). At the function level, PTX3 markedly decreased nitric oxide production when compared to vehicle (Fig. S9d ). Inhibition of MMP-1 by siRNA MMP1 hampered PTX3's deleterious effect on nitric oxide signaling, as revealed by a complete rescue of dimerization and phosphorylation of eNOS in serine 1177, effects associated with an enhanced production of nitric oxide (Fig. S9d) .
To clarify whether P-selectin, per se, was able to modulate MMP-1 signaling, we treated HUVEC with P-Selectin at different dosages. Although P-selectin did not change MMP-1 expression, it was able to significantly enhance its activity. This effect was lower compared to that observed in the presence of PTX3 (Fig. S9a, S9b ).
Hypertensive patients have elevated plasma levels of PTX3, P-selectin and MMP-1
Univariate tests showed that PTX3 (ng/mL), P-selectin (ng/mL) and MMP-1 (pg/mL) values were significantly higher in hypertensive subjects with respect to controls (p < 2 x 10 -8 ) (Table S1 ). It is important to underline that PTX3 was the strongest predictor of hypertension, reaching the highest p-value, as reported in Table S1 . The second goal of the analysis was to identify the most informative threshold for each variable to discriminate hypertensive subjects from controls. To this aim, the dataset was randomly split into a training set (37 subjects, 70% of the whole sample) and a test set (15 subjects, the remaining 30% of the data). Random sampling was performed with stratification, so that the proportion of cases and controls observed in the whole sample (60% vs.
40%) was maintained also in the two sub-cohorts. Thus, the training set was used to identify the most discriminative threshold for each variable, as described in Methods Section. The test set was then used to evaluate the discriminative performances corresponding to the variables discretized according to the identified threshold. Results are reported in Table S2 and show that PTX3 discretized according the threshold corresponding to ≥ 2.508 reaches the highest MCC, sensitivity and F-Measure among the analysed variables. Figure Legends . mesenteric arteries from wild-type (WT) and P-Selectin KO (P-sel -/-) mice: vessels were exposed to vehicle alone or to SAP for 45 minutes (200ng/mL); n=4 for each group. b) Dose-response curves to Ach of phenylephrine-precontracted mesenteric arteries from WT and P-Selectin KO mice: vessels were exposed to vehicle only or to CRP for 45 minutes (25mg/mL) n=4 for each group. ***, p<0.0001 vs WT. ###, p<0.0001 vs WT. 
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